PDS Biotech Announces Updated Survival Data From NCI-Led Phase 2 Clinical Trial Of PDS0101-Based Triple Combination Therapy In Advanced HPV16-Positive Cancer Patients which Show 75% Survival Of ICI Naïve Patients At 36 Months
Portfolio Pulse from Benzinga Newsdesk
PDS Biotech has announced updated survival data from a Phase 2 clinical trial of PDS0101-based triple combination therapy in advanced HPV16-positive cancer patients. The data shows a 75% survival rate at 36 months for ICI naive patients and a 72% 12-month survival rate for ICI resistant patients. The company's CEO, Frank Bedu-Addo, expressed optimism about the results and the potential for a registrational clinical trial of PDS0101 and PDS0301 in combination with a commercial ICI.
November 09, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotech's updated survival data from a Phase 2 clinical trial shows promising results, potentially leading to a registrational clinical trial of PDS0101 and PDS0301 in combination with a commercial ICI.
The positive results from the Phase 2 clinical trial could potentially lead to a new clinical trial, which would be a significant development for PDS Biotech. This could potentially increase investor interest and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100